Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Forte Biosciences Inc. (FBRX)
NASDAQ:FBRX
Holding FBRX?
Track your performance easily
FBRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.50 - $21.27
Previous Close$7.01
Volume1.74K
Average Volume (3M)5.56K
Market Cap
$10.35M
Enterprise Value-$14.27M
Total Cash (Recent Filing)$24.50M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 11, 2024EPS Estimate
-$6.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-21.42
Shares Outstanding1,460,158
10 Day Avg. Volume10,146
30 Day Avg. Volume5,562
Standard Deviation1.47
R-Squared0.00021
Alpha0.17
Financial Highlights & Ratios
Price to Book (P/B)0.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$109.38Price Target Upside1442.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Forte Biosciences News
PremiumCompany Announcements
Forte Biosciences Welcomes New Directors Amidst Strategic Changes
PremiumCompany Announcements
Forte Biosciences: Key Outcomes from 2024 Stockholders Meeting
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FBRX FAQ
What was Forte Biosciences Inc.’s price range in the past 12 months?
Forte Biosciences Inc. lowest stock price was $6.50 and its highest was $21.27 in the past 12 months.
What is Forte Biosciences Inc.’s market cap?
Currently, no data Available
When is Forte Biosciences Inc.’s upcoming earnings report date?
Forte Biosciences Inc.’s upcoming earnings report date is Nov 11, 2024 which is in 52 days.
How were Forte Biosciences Inc.’s earnings last quarter?
Forte Biosciences Inc. released its earnings results on Aug 14, 2024. The company reported -$6.75 earnings per share for the quarter, missing the consensus estimate of -$3.938 by -$2.812.
Is Forte Biosciences Inc. overvalued?
According to Wall Street analysts Forte Biosciences Inc.’s price is currently Undervalued.
Does Forte Biosciences Inc. pay dividends?
Forte Biosciences Inc. does not currently pay dividends.
What is Forte Biosciences Inc.’s EPS estimate?
Forte Biosciences Inc.’s EPS estimate is -$6.33.
How many shares outstanding does Forte Biosciences Inc. have?
Forte Biosciences Inc. has 1,460,158 shares outstanding.
What happened to Forte Biosciences Inc.’s price movement after its last earnings report?
Forte Biosciences Inc. reported an EPS of -$6.75 in its last earnings report, missing expectations of -$3.938. Following the earnings report the stock price went down -20.513%.
Which hedge fund is a major shareholder of Forte Biosciences Inc.?
Among the largest hedge funds holding Forte Biosciences Inc.’s share is Perceptive Advisors LLC. It holds Forte Biosciences Inc.’s shares valued at 2M.
---
Forte Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$109.38 (1442.74% Upside)
$109.38 (1442.74% Upside)
Hedge Fund Trend
Increased
By 58.0 Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.97%
12-Months-Change
Fundamentals
Return on Equity
-170.91%
Trailing 12-Months
Asset Growth
-16.37%
Trailing 12-Months
Company Description
Forte Biosciences Inc.
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.
---
FBRX Stock 12 Month Forecast
Average Price Target
$109.38
▲(1442.74% Upside)
Technical Analysis
180 Life Sciences
―
Cellectar Biosciences
―
Eloxx Pharmaceuticals
―
Comera Life Sciences Holdings
―
Best Analysts Covering FBRX
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-27.91%
reiterated a buy rating last month
Copying Michael Higgins's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -27.91% per trade.
---